Author

Nicolle H. Rekers

Observed names: N. Rekers, N.H. Rekers, Nicolle H Rekers, Nicolle Rekers, Rekers, Nicolle H.

Institution: Alfasigma (Italy)

Observed institutions: Maastricht University Medical Centre, Maastricht University, Alfasigma (Italy), Maastro Clinic, Amsterdam UMC Location Vrije Universiteit Amsterdam, Technical University of Denmark

ORCID: 0000-0003-4172-151X

Observed ORCID: 0000-0003-4172-151X

OpenAlex ID: A5050951636

Decision support systems for personalized and participative radiation oncology

2016 · Philippe Lambin, Jaap Zindler, et al. · Advanced Drug Delivery Reviews · 164

Combining radiotherapy with immunotherapy: the past, the present and the future

2017 · Evert J Van Limbergen, Dirk K De Ruysscher, et al. · British Journal of Radiology · 105

Radiotherapy Combined with the Immunocytokine L19-IL2 Provides Long-lasting Antitumor Effects

2014 · Catharina M.L. Zegers, Nicolle H. Rekers, et al. · Clinical Cancer Research · 99

New ways to image and target tumour hypoxia and its molecular responses

2015 · Ludwig J. Dubois, Raymon Niemans, et al. · Radiotherapy and Oncology · 60

The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses

2017 · Nicolle H. Rekers, Veronica Olivo Pimentel, et al. · OncoImmunology · 52

Combination of radiotherapy with the immunocytokine L19-IL2: Additive effect in a NK cell dependent tumour model

2015 · Nicolle H. Rekers, Catharina M.L. Zegers, et al. · Radiotherapy and Oncology · 36

Novel tools to assist neoepitope targeting in personalized cancer immunotherapy

2017 · S.K. Saini, N. Rekers, et al. · Annals of Oncology · 33

Stereotactic ablative body radiotherapy combined with immunotherapy: Present status and future perspectives

2014 · N.H. Rekers, E.G.C. Troost, et al. · Cancer/Radiothérapie · 33

Towards Tailored Therapy of Glioblastoma Multiforme

2011 · N.H. Rekers, P. Sminia, et al. · Journal of Chemotherapy · 25

Long-lasting antitumor effects provided by radiotherapy combined with the immunocytokine L19-IL2

2015 · Nicolle H Rekers, Catharina ML Zegers, et al. · OncoImmunology · 22

Multicentre, 26-week, open-label phase 2 trial of the JAK inhibitor filgotinib in Behçet’s disease, idiopathic inflammatory myopathies and IgG4-related disease: DRIMID study protocol

2025 · Bettina C Geertsema-Hoeve, Jan A M van Laar, et al. · BMJ Open · 12

OC-0051: Radiotherapy causes long-lasting antitumor immunological memory when combined with immunotherapy

2018 · V. Olivo Pimentel, N.H. Rekers, et al. · Radiotherapy and Oncology · 3

Cancer Immunotherapy: from the lab to clinical applications. Potential impact on cancer centres’ organisation

2016 · Linda Cairns, Sandrine Aspeslagh, et al. · ecancermedicalscience · 2

Data from Radiotherapy Combined with the Immunocytokine L19-IL2 Provides Long-lasting Antitumor Effects

2023 · Catharina M.L. Zegers, Nicolle H. Rekers, et al.

Supplementary Table 1 from Radiotherapy Combined with the Immunocytokine L19-IL2 Provides Long-lasting Antitumor Effects

2023 · Catharina M.L. Zegers, Nicolle H. Rekers, et al.

Supplementary Figure 1 from Radiotherapy Combined with the Immunocytokine L19-IL2 Provides Long-lasting Antitumor Effects

2023 · Catharina M.L. Zegers, Nicolle H. Rekers, et al.

Supplementary Figure 2 from Radiotherapy Combined with the Immunocytokine L19-IL2 Provides Long-lasting Antitumor Effects

2023 · Catharina M.L. Zegers, Nicolle H. Rekers, et al.

Supplementary Figure 3 from Radiotherapy Combined with the Immunocytokine L19-IL2 Provides Long-lasting Antitumor Effects

2023 · Catharina M.L. Zegers, Nicolle H. Rekers, et al.

Supplementary Figure 4 from Radiotherapy Combined with the Immunocytokine L19-IL2 Provides Long-lasting Antitumor Effects

2023 · Catharina M.L. Zegers, Nicolle H. Rekers, et al.

Supplementary Figure 3 from Radiotherapy Combined with the Immunocytokine L19-IL2 Provides Long-lasting Antitumor Effects

2023 · Catharina M.L. Zegers, Nicolle H. Rekers, et al.

Supplementary Figure 1 from Radiotherapy Combined with the Immunocytokine L19-IL2 Provides Long-lasting Antitumor Effects

2023 · Catharina M.L. Zegers, Nicolle H. Rekers, et al.

IL2 based immunotherapies: towards a personalized and curative antitumor response

2016 · Nicolle H. Rekers, Olivo Pimentel Veronica, et al. · Translational Cancer Research

SP-0575: Radiotherapy combined with immunotherapy: present status and future perspectives

2016 · P. Lambin, N. Rekers, et al. · Radiotherapy and Oncology

OC-0234: Radiotherapy and L19-IL2: perfect match for an abscopal effect with long-lasting memory

2016 · N.H. Rekers, A. Yaromina, et al. · Radiotherapy and Oncology

Radiotherapy and the immunocytokine L19-IL2: a perfect match for an abscopal effect with long-lasting memory

2016 · L. Dubois, N.H. Rekers, et al. · Radiotherapy and Oncology

Works count: 29

Citation count: 646

H-index: 11

I10-index: 11